Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS · NASDAQ Global Select
+$0.02 today
Vol 0.70M · Avg 0.40M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-172.3%
avg -29.6%
ROIC
-121.7%
avg -54.3%
ROA
-98.8%
avg -49.8%
Analysis
ROA is currently the strongest return metric at -98.8% versus its period average of -49.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Daniel J. O'Connell | Chief Executive Officer & Director | $972,747.00 | — | 56 | $881,275.00 | 1.45% |
James Doherty | President & Chief Development Officer | $764,370.00 | — | 58 | $250,300.00 | 0.41% |
Derek Meisner | Chief Legal Officer & Corporate Secretary | $752,945.00 | — | 55 | $176,089.00 | 0.29% |
Matt Zuga | Chief Financial Officer & Chief Business Officer | $681,780.00 | — | — | $304,924.00 | 0.50% |
Russell Barton | Chief Operating Officer | $223,680.00 | — | 67 | $205,092.00 | 0.34% |
Grant A. Krafft | Co-Founder | $42,000.00 | — | — | — | — |
William L. Klein | Co-Founder | $42,000.00 | — | — | $53,250.00 | 0.09% |
Caleb E. Finch | Co-Founder | $42,000.00 | — | — | — | — |
Alex Braun | Vice President & Head of Investor Relations | — | — | — | — | — |
Kelly Carranza | Senior Vice President of Finance & Accounting and Corporate Controller | — | — | — | — | — |
Robyn Moxon | Associate Director of Communications | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
48
$625,430.93
Net Sentiment
$625,430.93
Net selling
Most Active
Meisner Derek M
16 transactions
1–10 of 48
Analysis
Insiders reported 0 buys worth $0.00 and 48 sells worth $625,430.93 over the last 12 months. That adds up to net selling of $625,430.93. Meisner Derek M was the most active insider with 16 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Opus Genetics, Inc.
NASDAQ:IRD
$335.63M
Fate Therapeutics, Inc.
NASDAQ:FATE
$230.20M
Alector, Inc.
NASDAQ:ALEC
$182.64M
Spero Therapeutics, Inc.
NASDAQ:SPRO
$126.51M
Agenus Inc.
NASDAQ:AGEN
$123.26M
Seer, Inc.
NASDAQ:SEER
$94.57M
Seres Therapeutics, Inc.
NASDAQ:MCRB
$61.98M
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
$58.15M
Actuate Therapeutics Inc
NASDAQ:ACTU
$51.44M
VistaGen Therapeutics, Inc.
VTGN
$22.73M
Who manages ABOS?
Acumen Pharmaceuticals, Inc. (ABOS) lists 11 active executives. The top listed executive is Grant A. Krafft, Co-Founder.
Are ABOS insiders buying or selling?
Recent insider activity shows net buying of $74.71M.
Explore More
Continue the stock analysis
Jump to another research area for this company.